每天吃药、定期复查，血脂还是居高不下？高血脂，这一心脑血管疾病的「隐形杀手」，每年导致全球近400万人死亡。 而近期，《Nature ...

近期，武汉大学生命科学学院、泰康生命医学中心王琰课题组在Circulation（IF=35.5）发表题为“PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling”的研究论文，阐明了PCSK9促进LDL受体降解的作用机制，揭示了PCSK9药物抵抗的发生基础 我国心血管疾病患者 ...

Precision is also using its ARCUS platform to develop a treatment to edit PCSK9, a gene that regulates ... enable precise editing of the DNA of a living organism, opening up the possibility ...

Epigenetic editing is a promising method for gene regulation in vitro and in vivo, allowing precise control of gene expression without altering the DNA sequence, thereby minimizing genotoxic risks.

A single application of this innovative therapy slashed PCSK9 levels by an incredible 98 ... there was a slight interaction with other parts of the DNA; however, this did not alter the functioning ...

Through base editing, drugs replace single nucleotide in the DNA strand with another ... It will look at the effects of VERVE-101 on levels of PCSK9 and LDL cholesterol (LDC-c) in the blood ...

A single treatment cut PCSK9 levels by 98% and showed a “substantial ... they did notice some minor impact on other parts of the DNA. But this didn’t change how the affected genes worked ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...